(NYSE MKT: CUR) today published a blog post entitled “How
far that little candle throws his beams! So shines a good deed in a
weary world” on the Company’s website
which was republished on TheChairmansBlog.com.
and CEO, Richard Garr, blogs a group of young scientists in
Melbourne, Florida and their research project entitled “A study of
how microgravity affects the enzymes in ALS.” He highlights the
group’s efforts to raise awareness about ALS both in and out of the
patented technology enables the ability to produce neural stem cells
of the human brain and spinal cord in commercial quantities, and the
ability to control the differentiation of these cells constitutively
into mature, physiologically relevant human neurons and glia.
Neuralstem completed dosing of the last patient in an FDA-approved
Phase I safety clinical trial for amyotrophic lateral sclerosis
(ALS), often referred to as Lou Gehrig's disease, in August 2012; the
trial ends six months after that last surgery. Neuralstem has been
awarded orphan status designation by the FDA for its ALS cell
an exclusive, online media publication where publically and
privatively held firms alike share insights about their companies and
industries. TheChairmansBlog.com enables upper tier management to
discuss issues that are of importance to their stakeholders,
shareholders, and interested parties in an informal environment. In
addition to management`s insightful blog posts, TheChairmansBlog.com
staff and aggregate partners contribute articles on finance,
technology, health, and energy while providing updated market trends,
news, and information.
Source: Neuralstem, Inc.
Leave a comment...